AI
Thursday, April 12, 2007 11:33:57 PM
>>> and its a marathon, not a sprint. <<<
I'd be perfectly happy if I never heard that phrase again.
If you recall , that's how IDIX described the difference in viral load reduction rates between NM283 and VX-950 , and we know how that's working out.
At least the worst is over at EASL. The HBV stuff should be a little more uplifting.
The creative approach we need in HCV might be achieved thru creative deal-making with Schering to combo with their protease inhib. or with Achillon for their replicase inhib. , and then some creative arm-twisting at FDA to allow trials on combo investigational agents to move forward.
I'd be perfectly happy if I never heard that phrase again.
If you recall , that's how IDIX described the difference in viral load reduction rates between NM283 and VX-950 , and we know how that's working out.
At least the worst is over at EASL. The HBV stuff should be a little more uplifting.
The creative approach we need in HCV might be achieved thru creative deal-making with Schering to combo with their protease inhib. or with Achillon for their replicase inhib. , and then some creative arm-twisting at FDA to allow trials on combo investigational agents to move forward.
